Skip to main content

Advertisement

SpringerLink
Log in

Coronary heart disease in women: Hormone replacement therapy

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

  • For both primary and secondary prevention of coronary heart disease (CHD), it is prudent to use strategies that are of proven benefit and that do not harm patients. In all women, these strategies include lifestyle approaches such as smoking avoidance, proper nutrition, and regular exercise. Lipid-lowering and blood pressure control with pharmacotherapy are indicated in women who do not meet target lipid or blood pressure levels with lifestyle interventions. For women with CHD, aspirin, beta-blockers, and angiotensin-converting enzyme inhibitors should be considered. Widespread under-use of established preventive therapies has been documented in women. These interventions should be emphasized in clinical practice.

  • For secondary prevention of CHD in women, the American Heart Association (AHA) recommends against initiating hormone replacement therapy (HRT) based on studies that have shown no benefit and early harm. For patients with CHD already on HRT, the decision to continue or stop HRT should be based on established noncoronary benefits and risks and patient preference.

  • There are insufficient data to suggest that HRT should be initiated for the sole purpose of primary prevention of CHD.

  • Because the new AHA guidelines recommend placing significant weight on the noncardiac benefits and risks of HRT, it is important to become familiar with these noncardiac effects. It is also important to understand the evidence supporting the AHA’s decision to recommend placing relatively less weight on the cardiac effects of HRT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hulley S, Grady D, Bush T, et al.: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605–613. This randomized controlled trial (HERS) of Prempro vs placebo is the largest published secondary prevention trial of HRT in women with CHD. The results showed no benefit of HRT in cardiac morbidity or mortality after 4 to 5 years.

    Article  PubMed  CAS  Google Scholar 

  2. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995, 273:199–208.

  3. Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801–1811.

    Article  PubMed  CAS  Google Scholar 

  4. Jick H, Derby LE, Myers MW, et al.: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996, 348:981–983.

    Article  PubMed  CAS  Google Scholar 

  5. Daly E, Vessy MP, Hawkins MM, et al.: Risk of venous thromboembolism in user of hormone replacement therapy. Lancet 1996, 348:977–980.

    Article  PubMed  CAS  Google Scholar 

  6. Grady D, Wenger N, Herrington D, et al.: Postmenopausal hormone therapy increases risk of venous thromboembolic disease—the Heart and Estrogen/ progestin Replacement Study. Ann Intern Med 2000, 132:689–696.

    PubMed  CAS  Google Scholar 

  7. The Coronary Drug Project design and methods, and baseline results. Coronary Drug Project Research Group. Circulation 1973, 47(suppl 3):1–60.

  8. Stampfer MJ, Willett WC, Colditz GA, et al.: A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985, 313:1044–1049.

    Article  PubMed  CAS  Google Scholar 

  9. Wilson PW, Garrison RJ, Castelli WP: Postmenopausal estrogen use, cigarette smoking, and cardiovascular mortality in women over 50. The Framingham Study. N Engl J Med 1985, 313:1038–1043.

    Article  PubMed  CAS  Google Scholar 

  10. Grady D, Rubin SM, Petitti DB, et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016–1037.

    PubMed  CAS  Google Scholar 

  11. Sullivan JM, Vander Zwaag R, Lemp GF, et al.: Postmenopausal estrogen use and coronary athersclerosis. Ann Int Med 1988, 108:358–363.

    PubMed  CAS  Google Scholar 

  12. Matthews KA, Kuller LH, Wing RR, et al.: Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996, 143:971–978.

    PubMed  CAS  Google Scholar 

  13. Herrington DM, Reboussin DM, Brosnihan KB, et al.: Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000, 343:522–529. This randomized controlled trial (ERA) found no angiographic differences in 309 women randomized to Premarin, Prempro, or placebo.

    Article  PubMed  CAS  Google Scholar 

  14. Grodstein F, Manson JE, Stampfer MJ: Postmenopausal hormone use and secondary prevention of coronary events in the Nurses’ Health Study. Ann Intern Med 2001, 135:1–8.

    PubMed  CAS  Google Scholar 

  15. Heckbert SR, Kaplan RC, Weiss NS, et al.: Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001, 161:1709–1713.

    Article  PubMed  CAS  Google Scholar 

  16. Psaty B, Smith NL, Lemaitre RN, et al.: Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001, 285:906–913.

    Article  PubMed  CAS  Google Scholar 

  17. National Institutes of Health, National Heart, Lung, and Blood Institute. Women’s Health Initiative. URL: www.nhlbi.nih.gov/whi/hrt-en.htm; accessed December 14, 2001.

  18. Mosca L, Collins P, Herrington DM, et al.: Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001, 104:499–503. This article includes the American Heart Association’s November 2001 guidelines regarding HRT and cardiovascular disease in women and the evidence supporting these guidelines.

    PubMed  CAS  Google Scholar 

  19. The Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997, 350:1047–1059.

    Article  Google Scholar 

  20. Scgairer C, Lubin J, Troisi R, et al.: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000, 283:485–491.

    Article  Google Scholar 

  21. Ross R, Paganini-Hill A, Wan P, Pike M: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000, 92:328–332.

    Article  PubMed  CAS  Google Scholar 

  22. Simon JA, Hsia J, Cualey JA, et al.: Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001, 103:638–642.

    PubMed  CAS  Google Scholar 

  23. Viscoli CM, Brass LM, Kernan WN, et al.: Estrogen after ischemic stroke: effect of estrogen replacement on risk of recurrent stroke and death in the Women’s Estrogen for Stroke Trial (WEST) [abstract]. Stroke 2001, 32:329.

    Google Scholar 

  24. Cushing KL, Weiss NL, Voigt LF, et al.: Risk of endometrial cancer in relation to use of low-dose unopposed estrogens. Obstet Gynecol 1998, 91:35–39.

    Article  PubMed  CAS  Google Scholar 

  25. Grodstein F, Martinez E, Platz EA, et al.: Postmenopausal hormone use and risk of colorectal cancer and adenoma. Ann Intern Med 1998, 128:705–712.

    PubMed  CAS  Google Scholar 

  26. Yaffe K, Sawaya G, Lieberburg I, Grady D, et al.: Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998, 279:688–695.

    Article  PubMed  CAS  Google Scholar 

  27. Mulnard R, Cotman C, Kawas C, et al.: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000, 283:1007–1015.

    Article  PubMed  CAS  Google Scholar 

  28. Torgerson DJ, Bell-Syer SE: Hormone replacement therapy and prevention of non-vertebral fractures: a meta-analysis of randomized trials. JAMA 2001, 285:2909–2910.

    Article  Google Scholar 

  29. Greendale G, Reboussin B, Hogan P, et al.: Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstet Gynecol 1998, 92:982–988.

    Article  PubMed  CAS  Google Scholar 

  30. Stampfer MJ, Hu FB, Manson JE: Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000, 343:16–22.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of General Internal Medicine, University of California, San Francisco, 400 Parnassus Street, 94143-0346, San Francisco, CA, USA

    Mary S. Beattie MD & Rita Redberg MD

Authors
  1. Mary S. Beattie MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rita Redberg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beattie, M.S., Redberg, R. Coronary heart disease in women: Hormone replacement therapy. Curr Treat Options Cardio Med 4, 129–136 (2002). https://doi.org/10.1007/s11936-002-0033-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-002-0033-1

Keywords

Search

Navigation